Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 270 across all filing types
Latest filing 2025-06-30 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” under Canadian securities rules (NI 52-109). It is not the interim financial report or MD&A itself (IR), nor an announcement of report publication (RPA). It is a required certifying statement (a regulatory compliance form) submitted as part of the issuer’s filings. No other specific category applies, so it falls under the general “Regulatory Filings” fallback.
2025-06-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a proprietary regulatory certification (Form 52-109FV2) by the CFO certifying the company’s interim filings but does not include the interim financial statements or MD&A themselves. It is not an interim report (IR) nor is it an announcement of a report publication (RPA). It serves as a regulatory filing/certificate under Canadian securities rules and does not fit any other specific category, so the correct classification is the generic Regulatory Filings category (RNS).
2025-06-30 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is the full Management’s Discussion & Analysis for the three and six months ended April 30, 2025 and 2024, containing forward-looking statements, business overview, recent highlights, and detailed narrative of results and outlook. It is not an announcement of publication, nor an annual report, proxy, or earnings release. It matches the definition of a Management Report (MD&A) under Canadian continuous disclosure rules, providing management’s detailed explanation of financial results and trends. Therefore, it should be classified as a Management Report (MDA).
2025-06-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for BioVaxys Technology Corp. for the three and six months ended April 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Income/Loss, Statement of Shareholders' Equity, and Statement of Cash Flows) along with detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-06-30 English
Offering document (amended) - English.pdf
Capital/Financing Update Classification · 1% confidence The document is an “Amended Offering Document” under NI 45-106 describing a brokered private placement of units, pricing, warrants, closing dates, use of proceeds, and all terms of the securities offering. It’s a financing update outlining the company’s capital-raising activity, fitting squarely into the Capital/Financing Update category.
2025-06-20 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release detailing an amendment to the terms of a brokered private placement LIFE offering, including updated exercise prices, share consolidation details, unit pricing and use of proceeds. This is a clear update on the company’s fundraising and capital structure activities, fitting the definition of a Capital/Financing Update (CAP).
2025-06-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.